(13 Apr 2021) Niclosamide-UNI91104, a promising candidate for inhalation and intranasal therapy against COVID-19
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19 https://doi.org/10.1016/j.lanepe.2021.100084 NCT04576312- The trial was conducted between 29 June 2020 and 08 August 2020. Thirty-four healthy volunteers received UNI91104… Continue reading "(13 Apr 2021) Niclosamide-UNI91104, a promising candidate for inhalation and intranasal therapy against COVID-19"